DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Ottawa Marriott Hotel

2017年10月17日 (火) 午前 7:00 - 2017年10月18日 (水) 午後 3:00

100 Kent Street , Ottawa, ON K1P5R7 , CANADA

DIA Annual Canadian Meeting

Session 5B: Health Canada Policy Activities and Transparency Updates

Session Chair(s)

Karen  Feltmate

Karen Feltmate

President

Redstone Health Group, Inc., Canada

This session provides an opportunity for Health Canada to provide an update on key policy and regulatory activities. The department has a number of priorities which fall under its mandate, a few of which were discussed by senior government officials during the opening plenaries. This session delves deeper into additional policy and regulatory issues being led by the department. Leaders within the Health Products and Food Branch will provide timely updates on these initiatives, including outlining the policy objectives, the specific actions being implemented, and the applicable timelines. Whether you are in academia, industry, a not-for-profit, or a regulator, this information will help build your overall knowledge of issues affecting your work and the broader Canadian population as a whole.

Speaker(s)

Laura  Johnson

Update on Premarket Transparency Initiatives for Drugs and Medical Devices

Laura Johnson

Health Canada, Canada

Project Manager

Lucye  Galand, DVM, MBA, MSc

Anti-Microbial Resistance: An Overview of Health Canada's Activities

Lucye Galand, DVM, MBA, MSc

Health Canada, Canada

Acting Director, BGIVD, Therapeutic Products Directorate, HPFB

Celia  Lourenco, PhD

Regulatory Foresight: Anticipating the Health Needs of Canadians

Celia Lourenco, PhD

Health Canada, Canada

Director General, Biologic and Radiopharmaceutical Drugs Directorate, HPFB

Elizabeth  Toller, MA

Elizabeth Toller, MA

Health Canada, Canada

Associate Director General, Policy, Planning and International Affairs Directora

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。